These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29192474)

  • 1. Classical Kaposi's sarcoma concurrent with ledipasvir-sofosbuvir therapy for hepatitis C infection.
    Latini A; Orsini D; Ambrifi M; Colafigli M; Zaccarelli M; Cristaudo A
    G Ital Dermatol Venereol; 2019 Oct; 154(5):593-594. PubMed ID: 29192474
    [No Abstract]   [Full Text] [Related]  

  • 2. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
    [No Abstract]   [Full Text] [Related]  

  • 3. Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children.
    Rizza SA; Nehra V; Temesgen Z
    Drugs Today (Barc); 2017 Aug; 53(8):447-451. PubMed ID: 29119149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New-onset cutaneous lichen planus following therapy for hepatitis C with ledipasvir-sofosbuvir.
    Scott GD; Rieger KE
    J Cutan Pathol; 2016 Apr; 43(4):408-9. PubMed ID: 26816004
    [No Abstract]   [Full Text] [Related]  

  • 5. Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.
    Asahina Y; Itoh Y; Ueno Y; Matsuzaki Y; Takikawa Y; Yatsuhashi H; Genda T; Ikeda F; Matsuda T; Dvory-Sobol H; Jiang D; Massetto B; Osinusi AO; Brainard DM; McHutchison JG; Kawada N; Enomoto N
    Liver Int; 2018 Sep; 38(9):1552-1561. PubMed ID: 29297980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
    Smith MA; Chan J; Mohammad RA
    Ann Pharmacother; 2015 Mar; 49(3):343-50. PubMed ID: 25515863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.
    Lim YS; Ahn SH; Lee KS; Paik SW; Lee YJ; Jeong SH; Kim JH; Yoon SK; Yim HJ; Tak WY; Han SY; Yang JC; Mo H; Garrison KL; Gao B; Knox SJ; Pang PS; Kim YJ; Byun KS; Kim YS; Heo J; Han KH
    Hepatol Int; 2016 Nov; 10(6):947-955. PubMed ID: 27198664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive erosive lichen planus associated with hepatitis C responding to sofosbuvir/ledipasvir treatment.
    Morgado-Carrasco D; Combalia A; Fustà-Novell X; Mascaró JM; Iranzo P
    Indian J Dermatol Venereol Leprol; 2019; 85(3):326-329. PubMed ID: 30860163
    [No Abstract]   [Full Text] [Related]  

  • 9. A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6- to 12- year old children.
    El-Shabrawi MHF; Kamal NM; El-Khayat HR; Kamal EM; AbdElgawad MMAH; Yakoot M
    Aliment Pharmacol Ther; 2018 Jun; 47(12):1699-1704. PubMed ID: 29696674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C.
    Schwarz KB; Rosenthal P; Murray KF; Honegger JR; Hardikar W; Hague R; Mittal N; Massetto B; Brainard DM; Hsueh CH; Shao J; Parhy B; Narkewicz MR; Rao GS; Whitworth S; Bansal S; Balistreri WF
    Hepatology; 2020 Feb; 71(2):422-430. PubMed ID: 31220349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
    Modi AA; Nazario HE; Gonzales GR; Gonzalez SA
    Aliment Pharmacol Ther; 2018 May; 47(10):1409-1415. PubMed ID: 29569736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging options for treating hepatitis C infection.
    Fantasia HC
    Nurs Womens Health; 2015; 19(2):183-7. PubMed ID: 25900589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection.
    Graf Einsiedel H; Christiansen H; Wiegand J
    Pediatr Infect Dis J; 2016 Dec; 35(12):1373. PubMed ID: 27832030
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan.
    Liu CH; Liu CJ; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Kao JH
    PLoS One; 2018; 13(12):e0209299. PubMed ID: 30576344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of pembrolizumab while commencing treatment for hepatitis C with Harvoni (ledipasvir and sofosbuvir).
    Menon LL; Chin B; Khattak MA
    Intern Med J; 2018 Dec; 48(12):1542-1543. PubMed ID: 30517998
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis.
    Essa M; Sabry A; Abdelsameea E; Tharwa ES; Salama M
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):53-58. PubMed ID: 30247174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case of Erythema Multiforme Drug Eruption Induced by Ledipasvir/Sofosbuvir.
    Wang Y; Zheng S
    Am J Ther; 2018; 25(5):e586-e587. PubMed ID: 30188425
    [No Abstract]   [Full Text] [Related]  

  • 19. [All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
    Höner zu Siederdissen C; Cornberg M
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2411-4. PubMed ID: 25390631
    [No Abstract]   [Full Text] [Related]  

  • 20. [Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Ledipasvir / sofosbuvir-benefit assessment according to § 35a SGB V the G-BA].
    Berg T; Zeuzem S; Manns MP
    Z Gastroenterol; 2015 May; 53(5):519-23. PubMed ID: 26167554
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.